AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20668668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 18616783 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer A
Number of subjects: 14
Study 18616783 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer B
Number of subjects: 14
Study 18616783 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizer C
Number of subjects: 14
Study 18616783 — intervention group
Group type: COMPARATOR
Intervention: Control (no moisturizer)
Number of subjects: 14
Study 15068495 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg daily
Number of subjects: 593
Study 15068495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 593
Study 12059895 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Group P, bolus 1.5-2.0 mg/kg, maintenance 3.0-7.0 mg/kg/h) with remifentanil (10 microg/kg/h)
Number of subjects: 40
Study 12059895 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Group S, inhalational induction, end-tidal concentration 0.7-1.2 vol.%) with remifentanil (10 microg/kg/h)
Number of subjects: 40
Study 9524891 — intervention group
Group type: EXPERIMENTAL
Intervention: Simethicone
Number of subjects: 175
Study 9524891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 8562234 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 6.25 mg twice daily
Number of subjects: 20
Study 8562234 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol 25 mg daily
Number of subjects: 20
Study 2748256 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 40
Study 2748256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 668553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily for 4 weeks)
Number of subjects: 78
Study 668553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 668553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg daily long-term)
Number of subjects: 78
Study 668553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 78
Study 31923768 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 25 mg and Aspirin 100 mg
Number of subjects: 85
Study 31923768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 30661564 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Intervention (PFI)
Number of subjects: 198
Study 30661564 — intervention group
Group type: COMPARATOR
Intervention: Assessment Only (AO)
Number of subjects: 198
Study 30072210 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 0
Study 30072210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26908915 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 122
Study 26908915 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 122
Study 25428268 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus lightweight fibreglass heel casts
Number of subjects: 0
Study 25428268 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 23577699 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-induced postconditioning (0.1 mg/kg)
Number of subjects: 89
Study 23577699 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 89
Study 20078390 — intervention group
Group type: EXPERIMENTAL
Intervention: MNC+G-CSF
Number of subjects: 15
Study 20078390 — intervention group
Group type: COMPARATOR
Intervention: MNC-G-CSF
Number of subjects: 15
Study 18851797 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone morphogenetic proteins (BMPs)
Number of subjects: 30
Study 18851797 — intervention group
Group type: COMPARATOR
Intervention: Gold standard methods of autografting
Number of subjects: 30
Study 16816833 — intervention group
Group type: EXPERIMENTAL
Intervention: Day/Night dissociated formula milk
Number of subjects: 21
Study 16816833 — intervention group
Group type: COMPARATOR
Intervention: Standard formula milk (control)
Number of subjects: 21
Study 16816833 — intervention group
Group type: COMPARATOR
Intervention: Inverse control (Night/Day formula)
Number of subjects: 21
Study 12730559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate anticoagulation regimen (INR 2.0 to 3.0)
Number of subjects: 0
Study 12730559 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10741625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of 2 g cefpirome
Number of subjects: 12
Study 10741625 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 2 g cefpirome over 8 hours
Number of subjects: 12
Study 10741625 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of cefpirome
Number of subjects: 12
Study 10741625 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection and continuous infusion of cefpirome
Number of subjects: 12
Study 8841652 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram for alcohol cessation
Number of subjects: 0
Study 1392754 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline prescribed by a psychiatrist
Number of subjects: 121
Study 1392754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy from a clinical psychologist
Number of subjects: 121
Study 1392754 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling and case work by a social worker
Number of subjects: 121
Study 1392754 — intervention group
Group type: COMPARATOR
Intervention: Routine care by a general practitioner
Number of subjects: 121
Study 2951093 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread (90 g)
Number of subjects: 7
Study 2951093 — intervention group
Group type: COMPARATOR
Intervention: Spaghetti (65 g)
Number of subjects: 7
Study 2951093 — intervention group
Group type: EXPERIMENTAL
Intervention: Potatoes (285 g)
Number of subjects: 7
Study 31752769 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF monotherapy
Number of subjects: 46
Study 31752769 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy (PDT + anti-VEGF)
Number of subjects: 46
Study 31752769 — intervention group
Group type: COMPARATOR
Intervention: Deferred combination therapy (PDT + anti-VEGF)
Number of subjects: 46
Study 30286595 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotora-led physical activity intervention
Number of subjects: 614
Study 27227384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol HFA pMDI
Number of subjects: 16
Study 27227384 — intervention group
Group type: COMPARATOR
Intervention: Reference product (fluticasone/salmeterol HFA pMDI)
Number of subjects: 16
Study 24457901 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful smoking cessation
Number of subjects: 192
Study 24457901 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsuccessful smoking cessation
Number of subjects: 192
Study 22949147 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg intravenously) plus FOLFIRI
Number of subjects: 1226
Study 22949147 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus FOLFIRI
Number of subjects: 1226
Study 20012199 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ALERT curriculum (11 core lessons for sixth graders and 3 booster lessons for seventh graders)
Number of subjects: 34
Study 20012199 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ALERT curriculum
Number of subjects: 34
Study 18586927 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (6.75 microg/kg) every 4 weeks
Number of subjects: 218
Study 18586927 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks
Number of subjects: 218
Study 16113803 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d)
Number of subjects: 42
Study 16113803 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (160 mg/d)
Number of subjects: 42
Study 12395212 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min run (70 % of maximal speed)
Number of subjects: 18
Study 12395212 — intervention group
Group type: COMPARATOR
Intervention: Rest for 60 min
Number of subjects: 18
Study 10087117 — intervention group
Group type: EXPERIMENTAL
Intervention: True interval cancers
Number of subjects: 544
Study 10087117 — intervention group
Group type: COMPARATOR
Intervention: Missed interval cancers
Number of subjects: 544
Study 10087117 — intervention group
Group type: COMPARATOR
Intervention: Overlooked or misinterpreted tumours
Number of subjects: 544
Study 8775611 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with dilute povidone-iodine solution after primary reclosure (Group A)
Number of subjects: 55
Study 8775611 — intervention group
Group type: COMPARATOR
Intervention: Simple reclosure with drains in the mediastinum (Group B)
Number of subjects: 55
Study 3281708 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% fusidic acid
Number of subjects: 40
Study 3281708 — intervention group
Group type: COMPARATOR
Intervention: 0.3% gentamicin
Number of subjects: 40
Study 30204921 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil (4 tablespoons/day for 4 weeks)
Number of subjects: 25
Study 30204921 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil (4 tablespoons/day for 4 weeks)
Number of subjects: 25
Study 30204921 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 25
Study 30204921 — intervention group
Group type: COMPARATOR
Intervention: Coconut oil
Number of subjects: 25
Study 30204921 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil and Coconut oil
Number of subjects: 25
Study 29202862 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for Unusual Experiences (CBT-UED) plus routine care
Number of subjects: 100
Study 29202862 — intervention group
Group type: COMPARATOR
Intervention: Routine care alone
Number of subjects: 100
Study 26288022 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep quality (assessed with the Pittsburgh Sleep Quality Index)
Number of subjects: 158
Study 26288022 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective sleep quality
Number of subjects: 158
Study 26288022 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress (measured using the Brief Symptom Inventory‐18)
Number of subjects: 158
Study 23108011 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 300
Study 21962046 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Deprivation (FD) for up to 66 hours followed by 500 kcal intake over 24 hours
Number of subjects: 12
Study 21962046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) for up to 50 hours
Number of subjects: 12
Study 21962046 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Deprivation (FD) for up to 66 hours
Number of subjects: 12
Study 21962046 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) for 50 hours
Number of subjects: 12
Study 17621383 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with citalopram
Number of subjects: 15
Study 17621383 — intervention group
Group type: COMPARATOR
Intervention: Citalopram and placebo
Number of subjects: 15
Study 19933408 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 456
Study 19933408 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy in patients with Chagas disease
Number of subjects: 456
Study 15588157 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR 677C>T variant
Number of subjects: 591
Study 12100056 — intervention group
Group type: EXPERIMENTAL
Intervention: KLH-conjugated decapeptide vaccine (250 microg) administered intramuscularly, with three injections monthly and a booster 5 to 8 weeks later.
Number of subjects: 60
Study 12100056 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intramuscularly, with three injections monthly and a booster 5 to 8 weeks later.
Number of subjects: 60
Study 12100056 — intervention group
Group type: EXPERIMENTAL
Intervention: KLH-conjugated decapeptide vaccine (250 microg) administered intramuscularly.
Number of subjects: 60
Study 12100056 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intramuscularly.
Number of subjects: 60
Study 9590465 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene 30 g per day (15 g ointment twice a day for 14 days)
Number of subjects: 24
Study 9590465 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 24
Study 7871091 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of alpha-2 adrenoceptor antagonist
Number of subjects: 24
Study 7871091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2832091 — intervention group
Group type: EXPERIMENTAL
Intervention: DAMP-ES (schedule I: daily x5, doses of 10-90 mg/m2 per day)
Number of subjects: 0
Study 2832091 — intervention group
Group type: EXPERIMENTAL
Intervention: DAMP-ES (schedule II: 24-h continuous infusion, doses of 192 and 240 mg/m2)
Number of subjects: 0
Study 2832091 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended starting doses for phase II studies
Number of subjects: 0
Study 2832091 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic studies of DAMP-ES
Number of subjects: 0
Study 12375799 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11, Camptosar) and cisplatin
Number of subjects: 0
Study 12375799 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of taxanes and irinotecan
Number of subjects: 0
Study 30001358 — intervention group
Group type: EXPERIMENTAL
Intervention: Partograph utilization training
Number of subjects: 273
Study 30001358 — intervention group
Group type: EXPERIMENTAL
Intervention: Good knowledge about the partograph
Number of subjects: 273
Study 30001358 — intervention group
Group type: EXPERIMENTAL
Intervention: On the job training in obstetric care
Number of subjects: 273
Study 27425883 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative models after bimaxillary orthognathic surgery with bone trimming at the inferior edge of the pyriform aperture
Number of subjects: 10
Study 27425883 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mm stenosis models
Number of subjects: 10
Study 24738915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cu-IUD
Number of subjects: 150
Study 24738915 — intervention group
Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 150
Study 22991128 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 0
Study 22991128 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study 20547079 — intervention group
Group type: EXPERIMENTAL
Intervention: 980 nm laser with bare-tip fibres
Number of subjects: 60
Study 20547079 — intervention group
Group type: COMPARATOR
Intervention: 1470 nm laser with radial fibres
Number of subjects: 60
Study 18662179 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO detected by transesophageal echocardiography
Number of subjects: 203
Study 18662179 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO detected by catheter probing
Number of subjects: 203
Study 18662179 — intervention group
Group type: EXPERIMENTAL
Intervention: PFO presence
Number of subjects: 203
Study 18662179 — intervention group
Group type: COMPARATOR
Intervention: Overall procedural success
Number of subjects: 203
Study 15618041 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation at baseline
Number of subjects: 5477
Study 15618041 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset atrial fibrillation
Number of subjects: 5477
Study 11853793 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol (25 mg/kg 6 hourly)
Number of subjects: 1116
Study 11853793 — intervention group
Group type: COMPARATOR
Intervention: Benzylpenicillin (50 mg/kg 6 hourly) plus Gentamicin (7.5 mg/kg daily)
Number of subjects: 1116
Study 10442869 — intervention group
Group type: EXPERIMENTAL
Intervention: Context reminder 24 hr before the 6‐month interview
Number of subjects: 0
Study 10442869 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewed in the event context
Number of subjects: 0
Study 10442869 — intervention group
Group type: COMPARATOR
Intervention: Control group (reminder but not the event)
Number of subjects: 0
Study 10442869 — intervention group
Group type: EXPERIMENTAL
Intervention: Context reminder
Number of subjects: 0
Study 10442869 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal reminders
Number of subjects: 0
Study 7876913 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program including cognitive modification techniques and Stroebel's Quieting Response (QR) with biofeedback techniques
Number of subjects: 40
Study 7876913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 7876913 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program
Number of subjects: 40
Study 2230269 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic HIV-infected individuals
Number of subjects: 65
Study 2230269 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic individuals
Number of subjects: 65
Study 328527 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterimmunoelectrophoresis (CIEP)
Number of subjects: 51
Study 328527 — intervention group
Group type: COMPARATOR
Intervention: Complement fixation (CF) method
Number of subjects: 51
Study 31325068 — intervention group
Group type: COMPARATOR
Intervention: Spermatozoa from the first ejaculate after several days of abstinence (Group 1, N = 121)
Number of subjects: 265
Study 31325068 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatozoa from the second ejaculate after 1 hour of abstinence (Group 2, N = 144)
Number of subjects: 265
Study 28805147 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC lidocaine 3.6% with menthol 1.25%
Number of subjects: 87
Study 28805147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 28805147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rx lidocaine 5%
Number of subjects: 87
Study 26458124 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (250 μg or 500 μg)
Number of subjects: 1482
Study 23198836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella
Number of subjects: 60
Study 23198836 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 60
Study 23198836 — intervention group
Group type: COMPARATOR
Intervention: Eucerin
Number of subjects: 60
Study 21676368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration plus systemic hypothermia (33°C to 34°C) before first contrast injection and for 3 hours after the procedure
Number of subjects: 128
Study 21676368 — intervention group
Group type: COMPARATOR
Intervention: Hydration (control arm)
Number of subjects: 128
Study 19407711 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (fixed doses: 50, 100, 200, or 400 mg/day)
Number of subjects: 2913
Study 19407711 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (flexible doses: 100-400 mg/day)
Number of subjects: 2913
Study 19407711 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 2913
Study 19407711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2913
Study 16940855 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg elemental zinc twice daily for 14 days)
Number of subjects: 159
Study 16940855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical capsule for 14 days)
Number of subjects: 159
Study 14760933 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic radiographic contrast media (RCM)
Number of subjects: 37
Study 14760933 — intervention group
Group type: COMPARATOR
Intervention: Ionic radiographic contrast media (RCM)
Number of subjects: 37
Study 11081336 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile chronic arthritis group
Number of subjects: 0
Study 11081336 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 0
Study 8858666 — intervention group
Group type: EXPERIMENTAL
Intervention: BPIV-3 vaccine
Number of subjects: 30
Study 1518260 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 16
Study 1518260 — intervention group
Group type: COMPARATOR
Intervention: Postremission chemotherapy (CT-MC)
Number of subjects: 16
Study 6434387 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nisoldipine after acute administration
Number of subjects: 12
Study 6434387 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nisoldipine at the end of three weeks of treatment (10 mg twice daily)
Number of subjects: 12
Study 6434387 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg verapamil three times daily
Number of subjects: 12
Study 6434387 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during one-week wash-out period)
Number of subjects: 12
Study 31226936 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal treatment: therapeutic workout program + medication review + diet adjustment + health education
Number of subjects: 0
Study 31226936 — intervention group
Group type: COMPARATOR
Intervention: Control group: medication review + diet adjustment + health education (regular workout recommendations)
Number of subjects: 0
Study 31226936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 29548651 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTM (0.06mg/kg/day) for 6 days
Number of subjects: 80
Study 29548651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhTM)
Number of subjects: 80
Study 29548651 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTM treatment
Number of subjects: 80
Study 27574416 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast plus ICS/LABA FDC
Number of subjects: 2354
Study 27574416 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ICS/LABA FDC
Number of subjects: 2354
Study 25226757 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program (protocol-defined pharmacist care)
Number of subjects: 734
Study 25226757 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacist care (control group)
Number of subjects: 734
Study 22727500 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04457845 (4mg q.d.)
Number of subjects: 74